Reviewing Acutus Medical (NASDAQ:AFIB) & Bioventus (NYSE:BVS)

Acutus Medical (NASDAQ:AFIB) and Bioventus (NYSE:BVS) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their profitability, earnings, risk, valuation, institutional ownership, dividends and analyst recommendations.

Earnings and Valuation

This table compares Acutus Medical and Bioventus”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Acutus Medical	$7.16 million	0.00	-$81.66 million	N/A	N/A
Bioventus	$564.14 million	1.06	-$156.23 million	N/A	N/A

Acutus Medical has higher earnings, but lower revenue than Bioventus.

Volatility & Risk

Acutus Medical has a beta of -0.62, indicating that its share price is 162% less volatile than the S&P 500. Comparatively, Bioventus has a beta of 0.83, indicating that its share price is 17% less volatile than the S&P 500.

Profitability

This table compares Acutus Medical and Bioventus’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Acutus Medical	-272.74%	-311.64%	-11.57%
Bioventus	-7.11%	15.61%	4.01%

Analyst Ratings

This is a breakdown of recent recommendations and price targets for Acutus Medical and Bioventus, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Acutus Medical	0	0	0	0	0.00
Bioventus	0	1	3	0	2.75

Bioventus has a consensus target price of $13.75, indicating a potential upside of 90.71%. Given Bioventus’ stronger consensus rating and higher possible upside, analysts plainly believe Bioventus is more favorable than Acutus Medical.

Insider and Institutional Ownership

56.9% of Acutus Medical shares are held by institutional investors. Comparatively, 62.9% of Bioventus shares are held by institutional investors. 5.2% of Acutus Medical shares are held by company insiders. Comparatively, 33.0% of Bioventus shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Summary

Bioventus beats Acutus Medical on 11 of the 12 factors compared between the two stocks.

About Acutus Medical

Acutus Medical, Inc. designs, manufactures, and markets various tools for catheter-based ablation procedures to treat various arrhythmias in the United States and internationally. Its product portfolio includes novel access sheaths, transseptal crossing tools, diagnostic and mapping catheters, conventional and contact ablation catheters, and mapping and imaging consoles and accessories, as well as supporting algorithms and software programs. Acutus Medical, Inc. was incorporated in 2011 and is headquartered in Carlsbad, California.

About Bioventus

Bioventus Inc., a medical device company, focuses on developing and commercializing treatments that engage and enhance the body's natural healing process in the United States and internationally. The company's product portfolio includes pain treatments, which comprise non-surgical pain injection therapies, as well as peripheral nerve stimulation products, such as Durolane, GELSYN-3, and SUPARTZ for the treatment of knee osteoarthritis and Stimrouter to treat chronic peripheral pain. Its surgical solutions comprise bone graft substitutes that increase bone formation to stimulate bone healing in spinal fusions and other orthopedic surgeries; and ultrasonic products used for precise bone cutting and sculpting, soft tissue management, and tissue debridement, in various surgeries, including minimally invasive applications. The company's product include, Osteoamp, an allograft-derived bone graft for bone grafting procedures; Exponent matrix for posterolateral spine procedures; Purebone for bone grafting procedures; Signafuse bone graft; Interfuse bone graft; Osteomatrix+ synthetic bone graft; Extractor for autologous cell and bone marrow extraction; reficio bone matrix; nexus ultrasonic surgical system; bonescalpel surgical solution; SonaStar for surgical procedures; and SonicOne ultrasonic cleansing and debridement system. The company's restorative therapies include a bone stimulation system and devices to help patients regain leg or hand function due to stroke, multiple sclerosis, or other central nervous system disorders. Its products include exogen, a bone healing system; L300 GO, a foot drop system; H200 rehabilitation system; Vector, a body weight support system; and Bioness integrated therapy system. It developing Talisman pulse generator and receiver for peripheral nerve stimulation. The company was founded in 2011 and is headquartered in Durham, North Carolina.